GHK-Cu (Glycyl-L-Histidyl-L-Lysine bound to copper) is a naturally occurring tripeptide present in human plasma, saliva, and urine. Discovered in 1973 by Dr. Loren Pickart, it was initially identified for its ability to stimulate the survival and growth of liver tissue. Today, it is recognized as one of the most powerful epigenetic modulators available in longevity medicine.
Like many longevity molecules, endogenous GHK-Cu levels decline severely with age. At age 20, plasma levels are approximately 200 ng/mL. By age 60, they drop to 80 ng/mL. This decline correlates strongly with the loss of regenerative capacity in human tissue.
Broad-Spectrum Gene Modulation
The most remarkable property of GHK-Cu is its ability to modulate gene expression on a massive scale. Microarray analyses have demonstrated that GHK-Cu can upregulate or downregulate the expression of over 4,000 human genes—approximately one-third of the human genome—resetting their expression patterns to a younger, healthier state.
Specifically, GHK-Cu upregulates genes involved in DNA repair, antioxidant production, and tissue regeneration, while downregulating genes associated with chronic inflammation, cancer progression, and cellular senescence.
Tissue Regeneration and Collagen Synthesis
In the context of physical aging, GHK-Cu is best known for its profound effects on the extracellular matrix. It strongly stimulates the synthesis of collagen, elastin, and glycosaminoglycans in fibroblasts. Furthermore, it modulates the action of metalloproteinases—enzymes that break down damaged proteins—facilitating the removal of scarred, cross-linked tissue and replacing it with healthy, organized matrix.
This mechanism makes GHK-Cu exceptionally effective not only for aesthetic skin rejuvenation but for systemic tissue repair, including the healing of gastric ulcers, bone fractures, and damaged connective tissue.